-
Kang-Yin Chen,
Seung-Woon Rha, Lin Wang,
Yong-Jian Li,
Guang-Ping Li,
Kanhaiya L Poddar,
Ji-Young Park,
Cheol Ung Choi,
Chang-Gyu Park,
Hong Seog Seo, [......],
Myeong Chan Cho,
Jang Ho Bae,
Dong Hoon Choi,
Yang Soo Jang,
In Ho Chae,
Chong Jin Kim,
Jung Han Yoon,
Wook Sung Chung,
Ki Bae Seung,
Seung Jung Park
[show abstract]
[hide abstract]
ABSTRACT: This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting stents (ZES) in patients with acute myocardial infarction (AMI).
There is a paucity of data to exclusively evaluate the safety and efficacy of second-generation drug-eluting stents (DES) in the setting of AMI.
The present study enrolled 3,309 AMI patients treated with ZES (n = 1,608) or EES (n = 1,701) in a large-scale, prospective, multicenter registry-KAMIR (Korea Acute Myocardial Infarction Registry). Propensity score matching was applied to adjust for differences in baseline clinical and angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 receiving EES). Target lesion failure (TLF) was defined as the composite of cardiac death, recurrent nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year were compared between the 2 propensity score-matched groups.
After propensity score matching, baseline clinical and angiographic characteristics were similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year mortality, patients in the EES group had significantly lower rates of TLF (6.5% vs. 8.7%, p = 0.029) and probable or definite stent thrombosis (0.3% vs. 1.6%, p < 0.001), compared with those in the ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2% vs. 2.2%, p = 0.051) in the EES group than in the ZES group.
In this propensity-matched comparison, EES seems to be superior to ZES in reducing TLF and stent thrombosis in patients with AMI.
09/2012; 5(9):936-45. · 1.07 Impact Factor
-
Kang-Yin Chen,
Seung-Woon Rha,
Yong-Jian Li,
Zhe Jin,
Yoshiyasu Minami,
Ji Young Park,
Kanhaiya L Poddar,
Sureshkumar Ramasamy, Lin Wang,
Guang-Ping Li,
Cheol-Ung Choi,
Dong Joo Oh,
Myung Ho Jeong
[show abstract]
[hide abstract]
ABSTRACT: 1. Of the patients suffering from acute myocardial infarction (AMI), smokers are younger than non-smokers, which may be a major confounding factor causing 'smoker's paradox'. Therefore, in the present study we evaluated the 'smoker's paradox' in young patients with AMI.2. In all, 1218 young AMI patients (≤ 45 years of age), comprising 990 smokers and 228 non-smokers, were enrolled in the present study. In-hospital and 8 months clinical outcomes were compared between the smokers and non-smokers. 3. Baseline clinical characteristics showed that smokers were more likely to be male (97.9% vs 72.4%; P < 0.001) and had a higher rate of ST-segment elevation myocardial infarction (71.3% vs 59.5%; P = 0.001) than non-smokers. Clinical outcomes showed that smokers had lower rates of in-hospital cardiac death (0.8% vs 3.5%; P = 0.004), total death (0.8% vs 3.5%; P = 0.004) and 8 months cardiac death (1.1% vs 3.9%; P = 0.006) and total death (1.3% vs 4.4%; P = 0.005) than non-smokers. Multivariable logistic analysis showed that current smoking was an independent protective predictor of 8 months cardiac death (odds ratio (OR) 0.25; 95% confidence interval (CI) 0.07-0.92; P = 0.037) and total death (OR 0.26; 95% CI 0.09-0.82; P = 0.021). Subgroup analysis in patients who underwent percutaneous coronary intervention after AMI showed that current smoking was an independent protective predictor of 8 months total major adverse cardiac events (OR 0.47; 95% CI 0.23-0.97; P = 0.041). 4. Current smoking seems to be associated with better clinical outcomes in young patients with AMI, suggesting the existence of the 'smoker's paradox' in this particular subset of patients.
Clinical and Experimental Pharmacology and Physiology 05/2012; 39(7):630-5. · 1.85 Impact Factor
-
Yong-Jian Li,
Seung Woon Rha,
Kang-Yin Chen,
Zhe Jin, Lin Wang,
Sureshkumar Ramasamy,
Kanhaiya L Poddar,
Yoshiyasu Minami,
Ji-Young Park,
Cheol Ung Choi,
Dong Joo Oh,
Myung Ho Jeong
[show abstract]
[hide abstract]
ABSTRACT: Whether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractionated heparin (UFH) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear.
A total of 2397 NSTEMI patients who underwent PCI with DES received either LMWH [n=1178, subcutaneous enoxaparin 1 mg/kg, b.i.d., initiated after the patient's arrival and continued until 3-5 days after PCI plus reduced dose of UFH (50-70 U/kg) during PCI] or UFH (n=1219, 24,000U/day infusion, initiated after the patient's arrival and continued until at least 48 h after PCI). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared.
Enoxaparin group had similar incidences of cardiac death, total death, and total major adverse cardiac events (MACE) at 8 months compared with UFH group. The incidences of major and minor bleeding events were also similar between the two groups. Multivariable Cox regression analysis showed that enoxaparin group had similar incidences of cardiac death [adjusted odds ratio (OR) 1.16, 95% confidence interval (CI) 0.64-2.10, p=0.620], total death (adjusted OR 1.08, 95% CI 0.66-1.76, p=0.760), and total MACE (adjusted OR 0.94, 95% CI 0.69-1.28, p=0.692) at 8 months as compared with UFH group.
Enoxaparin with reduced dose of UFH only during PCI as an adjunctive antithrombotic therapy in NSTEMI patients undergoing PCI with DES was safe and showed comparable 8-month clinical outcomes as compared with UFH alone.
Journal of Cardiology 11/2011; 59(1):22-9. · 1.28 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the changes in drug treatment in elderly inpatients with chronic congestive heart failure (CHF) after the publication of the guideline.
Three thousands one hundred and seventy-four hospitalized patients over 60 years old with CHF admitted from January 1990 to July 2007 to Second Hospital of Tianjin Medical University were enrolled, and the patients were divided into three groups according to every 6 years by the time when guideline of the American College of Cardiology/American Heart Association (ACC/AHA) was published. The changes in drug treatment were analyzed retrospectively.
The proportion of enrolled patients was 79.2% (3 174/4 010) of total number of CHF patients. The number of male patients was 1 639, and that of the female 1 535. The age ranged 60-98 years old with the mean age (71.94±7.07) years old. Three groups were from 1990 to 1995 (group A), from 1996 to 2001 (group B) and from 2002 to 2007 (group C) respectively. The patients' age (years old) of three groups increased year by year (mean age of each group was 68.99±6.71, 71.56±6.86, 73.79±7.01 respectively, F=91.142, P<0.01). The three major causes of heart failure were coronary heart disease (55.3%, 64.5%, 81.8%), pulmonary heart disease (21.9%, 19.3%,5.5%) and rheumatic heart disease (16.5%, 10.3%, 7.5%). The difference among the three causes was statistically significant (χ(2)=217.979, P<0.01 ). Cardiac function on admission was mostly New York Heart Association (NYHA) grade III or IV (1 561 cases of NYHA III, 1 433 cases of NYHA IV, χ(2)=75.828, P<0.01 ). The outcome was mostly improved (the proportion of three groups was 88.9%, 88.3%, 92.7%, respectively, χ(2)=35.002, P<0.01). The frequency of using nitrate esters, β-blocker, angiotensin receptor blocker (ARB), aldosterone antagonist was increased year by year (all P<0.05). The use of digitalis was decreased gradually (both P<0.05). The angiotensin converting enzyme inhibitor (ACEI) and β-blocker were mostly used in coronary heart disease, and their frequency was 81.3% (1 698/2 088) and 87.8% (768/875) respectively.
The guidelines made positive effects on the treatment of elderly inpatients with CHF. The treatment drugs that can improve the prognosis of CHF should be used in this group in time.
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 10/2010; 22(10):606-9.
-
Seung-Woon Rha,
Yong-Jian Li,
Kang-Yin Chen,
Kanhaiya L Poddar,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Qun Dang,
Guang-Ping Li,
Sureshkumar Ramasamy, [......],
Yang Soo Jang,
In-Ho Chae,
Hyo-Soo Kim,
Chong Jin Kim,
Jung Han Yoon,
Tae Hoon Ahn,
Seung-Jea Tahk,
Wook Sung Chung,
Ki Bae Seung,
Seung-Jung Park
American heart journal 09/2010; 160(3):e27. · 4.65 Impact Factor
-
Seung-Woon Rha,
Yong-Jian Li,
Kang-Yin Chen,
Kanhaiya L Poddar,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Qun Dang,
Guang-Ping Li,
Sureshkumar Ramasamy, [......],
Yang Soo Jang,
In-Ho Chae,
Hyo-Soo Kim,
Chong Jin Kim,
Jung Han Yoon,
Tae Hoon Ahn,
Seung-Jea Tahk,
Wook Sung Chung,
Ki Bae Seung,
Seung-Jung Park
American heart journal 08/2010; 160(2):e15-6. · 4.65 Impact Factor
-
Sunil P Wani,
Seung-Woon Rha,
Ji Young Park,
Kanhaiya L Poddar, Lin Wang,
Sureshkumar Ramasamy,
Ji Mi Moon,
Ji Bak Kim,
Sang Ryol Ryu,
Seung Yong Shin,
Un-Jung Choi,
Cheol Ung Choi,
Hong Euy Lim,
Jin Won Kim,
Eung Ju Kim,
Chang Gyu Park,
Hong Seog Seo,
Dong Joo Oh
[show abstract]
[hide abstract]
ABSTRACT: Break of a stent delivery catheter and subsequent stent loss (SL) has been a rare event in the drug-eluting stent (DES) era. We here report a case of successful retrieval of a stent after a break if the delivery catheter and SL from a balloon catheter at a culprit lesion. We finally resolved this situation using a simple balloon technique for both the broken stent catheter inside of the guide catheter and the unexpanded stent in the culprit lesion. Thus balloons are an important weapon in our armamentarium in the cardiac catheterization laboratory for urgent retrieval of a lost stent. Their apt use definitely allowed our patient to avoid undergoing emergency cardiovascular thoracic surgery.
Korean Circulation Journal 08/2010; 40(8):405-9.
-
Yong-Jian Li,
Seung-Woon Rha,
Kang-Yin Chen,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Qun Dang,
Kanhaiya L Poddar,
Sureshkumar Ramasamy,
Ji-Young Park,
Dong Joo Oh,
Myung Ho Jeong
[show abstract]
[hide abstract]
ABSTRACT: 1. The aim of the present study was to evaluated the impact of prior cerebrovascular disease (CVD) on the clinical characteristics and mid-term clinical outcomes of patients with acute myocardial infarction (AMI) in the era of drug-eluting stents. 2. Data from 12 914 patients with acute myocardial infarction who were enrolled in the Korea Acute Myocardial Infarction Registry were analysed retrospectively from November 2005 to December 2007. Prior CVD was defined as having had one or more events of ischaemic or haemorrhagic stroke or a transient ischaemic attack. 3. Of the 12 914 patients reviewed, 906 (7.0%) were found to have had prior CVD. Patients with CVD were older, were more likely to be women and were more likely to have hypertension and diabetes than those without CVD. Patients with prior CVD presented more often with non-ST-segment elevation myocardial infarction and higher Killip class than those without CVD. Furthermore, patients with CVD received less percutaneous coronary intervention (PCI) or thrombolysis compared with those without CVD. Although intensive medical therapy was equal in both groups, clinical outcomes at 8 months showed that patients with CVD had a higher incidence of cardiac death (adjusted odds ratio (OR) 1.42; 95% confidence interval (CI) 1.14-1.76; P = 0.002) and total death (adjusted OR 1.50; 95% CI 1.25-1.81; P < 0.001) than those without CVD. 4. In conclusion, patients with prior CVD presented with worse clinical characteristics on admission and were less likely to receive PCI or thrombolysis than those without CVD. Given the poorer mid-term clinical outcomes, more intensive and aggressive management shouldis recommended for patients with prior CVD to improve their long-term clinical outcome.
Clinical and Experimental Pharmacology and Physiology 05/2010; 37(5-6):581-6. · 1.85 Impact Factor
-
Yong-Jian Li,
Seung-Woon Rha,
Kang-Yin Chen,
Kanhaiya L Poddar,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Qun Dang,
Guang-Ping Li,
Sureshkumar Ramasamy, [......],
Yang Soo Jang,
In Ho Chae,
Hyo Soo Kim,
Chong Jin Kim,
Jung Han Yoon,
Tae Hoon Ahn,
Seung-Jea Tahk,
Wook Sung Chung,
Ki Bae Seung,
Seung Jung Park
[show abstract]
[hide abstract]
ABSTRACT: Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) remains unclear.
A total of 3,372 STEMI patients who underwent primary PCI with DESs received either LMWH (n = 1,531 patients, subcutaneous enoxaparin 1 mg/kg, bid for 3-5 days plus reduced dose of UFH [50 U/kg] during PCI) or UFH alone (n = 1,841 patients, intravenous bolus injection of 5,000 U, followed by 24,000 U/d infusion for at least 48 hours). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared.
The incidences of major and minor bleeding events were similar between the 2 groups. Multivariable Cox regression analysis showed that LMWH group had lower incidences of cardiac death (adjusted odds ratio [OR] 0.55, 95% CI 0.39-0.77, P < .001), total death (adjusted OR 0.50, 95% CI 0.37-0.68, P < .001), and total major adverse cardiac events (adjusted OR 0.77, 95% CI 0.62-0.95, P = .017) at 8 months as compared with UFH group. Similar results were obtained across different subgroups including different DESs, age, and sex.
The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion.
American heart journal 04/2010; 159(4):684-690.e1. · 4.65 Impact Factor
-
Kang-Yin Chen,
Seung-Woon Rha,
Yong-Jian Li,
Kanhaiya L Poddar,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Guang-Ping Li,
Shigeru Saito,
Jae-Hyoung Park,
Jin-Oh Na,
Cheol Ung Choi,
Hong-Euy Lim,
Jin-Won Kim,
Eung-Ju Kim,
Chang-Gyu Park,
Hong-Seog Seo,
Dong-Joo Oh
[show abstract]
[hide abstract]
ABSTRACT: 1. Both peripheral arterial disease (PAD) and coronary artery spasm (CAS) are associated with endothelial dysfunction. Thus, a higher incidence of CAS may be expected in patients with PAD. In the present study, we evaluated the incidence and characteristics of CAS in patients with PAD. 2. A total of 78 patients with PAD and 241 age- and gender-matched patients without PAD who had chest pain with normal coronary appearance on coronary angiograms underwent intracoronary acetylcholine (ACh) provocation test. Acetylcholine was injected into the left coronary artery in incremental doses of 20, 50 and 100 microg/min. Significant CAS was defined as a transient > 70% luminal narrowing with concurrent chest pain and/or ST segment changes. 3. Patients with PAD had a significantly higher incidence of ACh-induced significant CAS than those without PAD (60.3 vs 34.0%, respectively P < 0.001), as well as chest pain and ST segment changes during the ACh provocation test. Patients with PAD were more sensitive to lower doses of ACh and had a higher incidence of multivessel spasm than those without PAD. Multivariable logistic analysis showed that age, current smoking, PAD and myocardial bridge were independent predictors of ACh-induced significant CAS. Moreover, of these factors, PAD was the strongest independent predictor (odds ratio 4.25; confidence interval 1.33-13.54; P = 0.014). 4. In patients with chest pain, the presence of arterial disease at another site should still push the clinician towards treating the chest pain as angina, even if the coronary anatomy is normal on a coronary angiogram.
Clinical and Experimental Pharmacology and Physiology 09/2009; 36(11):e78-82. · 1.85 Impact Factor
-
Chinese medical journal 09/2009; 122(18):2174-9. · 0.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To analyze the impact of renal dysfunction on survival in hospitalized chronic heart failure (CHF) patients.
In this retrospective analysis, we collected all clinical data from eligible patients hospitalized in the second hospital of Tianjin Medical University between Jan 1980 and Aug 2007. CHF patients were divided into three groups according to glomerular filtration rate (GFR): A, normal renal function; B, mild renal dysfunction; C, renal dysfunction. Patients in group C were further divided into three subgroups according to hospitalization year: D, 1980.01 - 1989.12; E, 1990.01 - 1999.12; F, 2000.01 - 2007.08.
Renal dysfunction was found in 714 patients. Compared with group A (n = 817) and group B (n = 928), patients in group C were older, had worse heart function and major medications included nitrates, diuretics and digitalis. From 1980 to 2007, use of Angiotensin II receptor antagonist, beta-blocker, statins significantly increased and the in-hospital mortality significantly decreased in group C patients. Percent of angiotensin converting enzyme inhibitor (ACEI) use was the highest in 1990s. The hospital stay was significantly longer and all cause in-hospital mortality was significantly higher in group C compared to group A and group B (all P < 0.01). After adjustment for other risk factors by multivariate analysis, renal dysfunction was an independent risk factor of in-hospital all cause mortality. Patients faced 16.7% higher risk of all cause in-hospital mortality for every 10 mlxmin(-1) x1.73 m(-2) decrease in GFR.
The incidence of renal dysfunction was high in CHF patients. The hospital stay was longer, in-hospital all-cause mortality was higher in CHF patients with renal dysfunction compared to CHF patients without or with mild renal dysfunction. Renal dysfunction was an independent risk factor for all-cause in-hospital mortality. Increased use of ACEI, ARB, beta-blocker and statins might be responsible for reduced in-hospital mortality in CHF with renal dysfunction patients in recent years.
Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases] 08/2009; 37(8):729-33.
-
Kang-Yin Chen,
Seung-Woon Rha,
Yong-Jian Li,
Kanhaiya L Poddar,
Zhe Jin,
Yoshiyasu Minami, Lin Wang,
Eung Ju Kim,
Chang Gyu Park,
Hong Seog Seo, [......],
Myeong Chan Cho,
Jang Ho Bae,
Dong Hoon Choi,
Yang Soo Jang,
In Ho Chae,
Chong Jin Kim,
Jung Han Yoon,
Wook Sung Chung,
Ki Bae Seung,
Seung Jung Park
[show abstract]
[hide abstract]
ABSTRACT: Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug-eluting stents remains unclear.
A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents were analyzed retrospectively in the Korean Acute Myocardial Infarction Registry (KAMIR). They received either dual (aspirin plus clopidogrel; dual group; n=2569) or triple (aspirin plus clopidogrel plus cilostazol; triple group; n=1634) antiplatelet therapy. The triple group received additional cilostazol at least for 1 month. Various major adverse cardiac events at 8 months were compared between these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. Clinical outcomes at 8 months showed that the triple group had significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84; P=0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P=0.010), and total major adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 to 0.95; P=0.019) than the dual group. Subgroup analysis showed that older (>65 years old), female, and diabetic patients got more benefits from triple antiplatelet therapy than their counterparts who received dual antiplatelet therapy.
Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These results may provide the rationale for the use of triple antiplatelet therapy in these patients.
Circulation 07/2009; 119(25):3207-14. · 14.74 Impact Factor
-
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 05/2008; 20(4):247-8.
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate drug treatment of inpatients with chronic heart failure(CHF) during the past 30 years in some areas and to provide more information on the treatment strategy of CHF.
In two centers a retrospective study was conducted. All data were taken from the hospitalized cases with chronic heart failure. The medication distributions in different decade, gender, age heart function grade and etiology were analyzed.
5189 cases were enrolled with the ratio of male to female as 1:1.02. The mean age was (62.93 +/- 13.49) years old. The general causes of chronic heart failure were as follows: coronary heart disease (44.2%), rheumatic heart disease (24.1% ) , pulmonary heart disease (19.0%) and cardiomyopathy (4.8%). The admission cardiac function was mostly seen as grade NYHA IlI and IV, and their proportions were 40.6% and 44.5%. Major medication would include nitride (80.0%), diuretics (71.8% ), digitalis (68.1% ), angiotensin conversion enzyme inhibitors (ACEI) (52.2% ) and beta-blockers (19.5% ) etc. Moreover the frequency of above used medication was essentially increasing decade by decade. The major drug treatment of pulmonary heart disease also included diuretics, nitride, digitalis. ACEI was more commonly used in male than in female cases. The frequency of ACEI and ARB were more commonly used in the group > or = 60 years old than that in the group < 60 years old. The administration frequency of beta- blockers had no significant difference among different age and sexes.
The conventional drugs such as nitride, diuretics, digitalis were still dominated the treatment of CHF. Although the administration frequency of ACEI and beta-blockers increased quickly, there had been a great gap between the optimal medical strategy and clinical practice in the management of CHF. Data showed the treatment strategy was changing.
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 02/2007; 28(1):78-82.
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and atrium natriuretic peptide (ANP) in chronic congestive heart failure.
Seventy-one coronary heart disease patients were enrolled in the study. Among them 58 patients were accompanied by heart failure and 13 with no heart failure. Plasma NT-ProBNP was determined with enzyme linked immunoadsorbent assay method, and plasma ANP was determined with radioimmunoassay method. The results were compared with those of 30 healthy individuals. All patients were followed up accordingly.
Compared with patients with no heart failure and healthy individuals, the patients with heart failure had a higher plasma NT-proBNP and ANP contents. Cardiac function grade IV patients had a significantly higher plasma NT-ProBNP than cardiac function grade II and III patients, and their plasma ANP level was significantly higher than that of cardiac function grade III patients, but there was no significantly difference in ANP content between cardiac function grade IV and II. The diagnostic sensitivity of NT-proBNP and ANP was 94.38% and 75.86%, respectively. The diagnostic specificity of NT-proBNP and ANP was 96.67%, 83.33%, respectively. In the heart failure group, after being followed up for (11.35+/-1.69) months, it was found that there was no significant difference in the plasma NT-proBNP and ANP between the deaths and surviving patients.
The diagnostic value of NT-proBNP in chronic heart failure is higher than that of ANP. According to our follow-up result, the plasma NT-proBNP and ANP can not be relied upon to predict short-term cardiogenic death in heart failure.
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 10/2005; 17(9):544-7.
